Lung cancer drug nivolumab now available through CDF

  Lung cancer patients in England can now be prescribed nivolumab, also known as Opdivo, after NICE says it should be available through the Cancer Drugs Fund (CDF). Around 1,300 lung cancer patients will receive nivolumab as part of a CDF deal put forward by makers Bristol-Myers Squibb. Nivolumab has been widely described as a breakthrough drug. When NICE first reviewed it, they said the evidence was not strong enough to recommend nivolumab for routine NHS use. However, as nivolumab appeared to be more effective in some patients, NICE asked Bristol-Myers Squibb to make it available with a discount whilst